Skip to Content

'
Lance C. Pagliaro, M.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1155 Pressler St.
Unit Number: 1374
Houston, TX 77030
Room Number: CPB7.3458
Phone: 713-792-2830
Fax: 713-794-1446

Education & Training

Degree-Granting Education

1987 Albany Medical College, Albany, NY, MD, Medicine
1983 Amherst College, Amherst, MA, BA, Magna Cum Laude, Biology and Anthropology

Postgraduate Training

7/1992-6/1993 Clinical Fellowship, Hematology and Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
7/1990-6/1992 Clinical Fellowship, Hematology and Medical Oncology, The George Washington University Medical Center, Washington, DC
7/1988-6/1990 Clinical Residency, Internal Medicine, The George Washington University Medical Center, Washington, DC
7/1987-6/1988 Clinical Internship, Internal Medicine, The George Washington University Medical Center, Washington, DC

Board Certifications

1999 American Board of Medical Oncology
1994 American Board of Hematology
1990 American Board of Internal Medicine
1988 National Board of Medical Examiners

Experience/Service

Academic Appointments

Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2004-8/2012
Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, 1995-2004
Faculty Associate, Department of Clinical Investigation, Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1993-1995
Junior Faculty Associate, Department of Medical Specialties, Division of Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, 1992-1993

Selected Publications

Peer-Reviewed Original Research Articles
1. Sonpavde G, Pagliaro LC, Buonerba C, Dorff TB, Lee RJ, Di Lorenzo G. Penile cancer: current theapy and future directions. Ann Oncol. e-Pub 1/4/2013. PMID: 23293117.
2. Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L, Smith L, Lim Z, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood CG, Jonasch E. A Phase 2 Trial of Sunitinib in Patients with Advanced Non-clear Cell Renal Cell Carcinoma. Eur Urol 62(6):1013-9, 12/2012. e-Pub 6/27/2012. PMID: 22771265.
3. Rodney AJ, Tannir NM, Siefker-Radtke AO, Liu P, Walsh GL, Millikan RE, Swisher SG, Tu SM, Pagliaro LC. Survival outcomes for men with mediastinal germ-cell tumors: The University of Texas MD Anderson Cancer Center experience. Urol Oncol 30(6):879-85, Nov-Dec, 11/2012. e-Pub 10/8/2010. PMID: 20933444.
4. Dayyani F, Pettaway CA, Kamat AM, Munsell MF, Sircar K, Pagliaro LC. Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists. Urol Oncol. e-Pub 4/23/2012. PMID: 22534087.
5. Osai WE, Demicco EG, Pagliaro LC. Malignant Small Round Blue Cell Tumor of the Kidney Without EWSR1 Rearrangement: Report of a Case and Review of the Literature. Clin Genitourin Cancer 10(1):63-5, 3/2012. PMID: 22153153.
6. Mathew P, Tannir N, Tu SM, Wen S, Guo CC, Marcott V, Bekele BN, Pagliaro L. Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib. Cancer Chemother Pharmacol 68(4):889-96, 10/2011. PMID: 21290244.
7. Hegarty PK, Suh J, Fisher MB, Taylor J, Nguyen TH, Ivan D, Prieto VG, Pagliaro LC, Pettaway CA. Penoscrotal Extramammary Paget Disease: The University of Texas M. D. Anderson Cancer Center (MDACC) Contemporary Experience. J Urol 186(1):97-102, 7/2011. e-Pub 5/14/2011. PMID: 21571343.
8. Tzelepi V, Efstathiou E, Wen S, Troncoso P, Karlou M, Pettaway CA, Pisters LL, Hoang A, Logothetis CJ, Pagliaro LC. Persistent, biologically meaningful prostate cancer after one year of androgen ablation and docetaxel treatment. J Clin Oncol 29(18):2574-81, 6/20/2011. e-Pub 5/23/2011. PMCID: PMC3138635.
9. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Tamboli P, Patel KK, Matin SF, Wood CG, Tannir NM. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol 22(5):1048-53, 5/2011. e-Pub 11/2010. PMID: 21115604.
10. Jonasch E, Lal LS, Atkinson BJ, Byfield SD, Miller LA, Pagliaro LC, Feng C, Tannir NM. Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre. BJU Int 107(5):741-7, 3/2011. e-Pub 9/21/2010. PMID: 21355978.
11. Watkins JL, Atkinson BJ, Pagliaro LC. Rhabdomyolysis in a Prostate Cancer Patient Taking Ketoconazole and Simvastatin: Case Report and Review of the Literature. Ann Pharmacother. e-Pub 2/2011. PMID: 21304039.
12. Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro LC, Beer TM, Liu G, Small EJ. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the department of defense prostate cancer clinical trials consortium. Cancer. e-Pub 12/29/2010. PMID: 21192058.
13. Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA. Neoadjuvant Paclitaxel, Ifosfamide, and Cisplatin Chemotherapy for Metastatic Penile Cancer: A Phase II Study. J Clin Oncol 28(24):3851-7, 8/20/2010. e-Pub 7/12/2010. PMCID: PMC2940402.
14. Mathew P, Tannir N, Tu SM, Carter CM, Bekele NB, Pagliaro L. A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy. Cancer Chemother Pharmacol 65(4):811-5, 3/2010. PMID: 20052472.
15. Jonasch E, Corn P, Pagliaro LC, Warneke CL, Johnson MM, Tamboli P, Ng C, Aparicio A, Ashe RG, Wright JJ, Tannir NM. Upfront, randomized, phase 2 trial of sorafenib versus sorfenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 116(1):57-65, 1/1/2010. PMID: 19862815.

Invited Articles
1. Pagliaro LC, Tannir N, Sircar K, Jonasch E. Systemic therapy for sarcomatoid renal cell carcinoma. Expert Rev Anticancer Ther 11(6):913-20, 6/2011. PMID: 21707288.
2. Jonasch E, Pagliaro LC, Tannir NM. Long-term management of patients with metastatic renal cell carcinoma on targeted agents. Expert Rev Anticancer Ther 10(12):1883-9, 12/2010. PMID: 21110755.
3. Pettaway CA, Pagliaro L, Theodore C, Haas G. Treatment of visceral, unresectable, or bulky/unresectable regional metastases of penile cancer. Urology 76(2 Suppl 1):S58-65, 8/2010. PMID: 20691886.
4. Pagliaro LC. Testicular Cancer: When Less is More. Curr Oncol Rep 12(4):271-77, 7/2010. PMID: 20443156.

Last updated: 3/5/2013